sevelamer (RenaGel)

RN given for HCl salt; structure in first source; a crosslinked polymeric amine that binds PHOSPHATES and BILE ACIDS; it is nonabsorbed; used for hyperphosphatemia during HEMODIALYSIS and in END-STAGE RENAL DISEASE; used like calcium acetate

Also Known As:

Networked: 284 relevant articles (47 outcomes, 70 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Burke, Steven K: 10 articles (12/2008 - 07/2002)
2.	Ketteler, Markus: 7 articles (06/2015 - 11/2005)
3.	Nagano, Nobuo: 7 articles (03/2006 - 06/2003)
4.	Chertow, Glenn M: 5 articles (05/2014 - 07/2002)
5.	Slatopolsky, Eduardo: 5 articles (12/2013 - 09/2002)
6.	Cozzolino, Mario: 5 articles (03/2012 - 09/2002)
7.	Fukushima, Naoshi: 5 articles (06/2004 - 06/2003)
8.	Maizel, Julien: 4 articles (11/2014 - 11/2005)
9.	Massy, Ziad A: 4 articles (11/2014 - 11/2005)
10.	Keith, Michael S: 4 articles (10/2014 - 12/2011)

Related Diseases

1.	Hyperphosphatemia 11/01/2014 - "Sevelamer is a phosphate binder that allows a better control of hyperphosphatemia, like other phosphate binder agents, but it has additional pleiotropic effects such as correcting certain abnormalities of lipid metabolism and clearance of several uremic toxins. " 07/01/2008 - "Sevelamer is a phosphate-binder used effectively for the treatment of hyperphosphatemia in patients treated with dialysis. " 12/01/2007 - "Sevelamer appears useful for the treatment of hyperphosphatemia in these patients. " 10/01/2008 - "In addition, the efficacy of sevelamer as a monotherapy in lowering phosphate to target levels in severe hyperphosphatemia remains debatable. " 06/01/2015 - "In this study, we attempted to create a peptide specific antibody that produced outcomes similar to those of the human pharmaceutical, sevelamer HCl, used in the treatment of hyperphosphatemia (a sequela of chronic renal disease). "
2.	Hypercalcemia (Milk Alkali Syndrome) 04/01/2006 - "The marked decrease in lipid levels and lower rate of hypercalcemia may augment the long-term benefit of sevelamer." 01/01/2015 - "This meta-analysis suggests that sevelamer benefits dialysis patients in terms of CACS, ACS and hypercalcemia." 05/01/2014 - "However, sevelamer hydrochloride seems to be superior among all with lowering incidence of hypercalcemia. " 01/01/2014 - "Sevelamer hydrochloride has been introduced as an efficient medication for phosphate control, with a lower risk of hypercalcemia and parathyroid suppression. " 06/01/2004 - "The incidence of hypercalcemia for sevelamer was not different from the incidence of hypercalcemia during the washout period. "
3.	Chronic Kidney Failure (Chronic Renal Failure) 12/01/2013 - "Endothelial effects of sevelamer may contribute mechanistically to the improved survival observed in some studies of CKD and ESRD patients." 05/01/2013 - "Clinical efficacy of sevelamer hydrochloride in patients with end-stage renal disease: a retrospective study." 09/01/2005 - "The safety and efficacy of sevelamer hydrochloride in binding phosphate in patients with end-stage renal disease and its ability to attenuate the progression of cardiac calcification have been well documented but not the longer-term health and economic implications. " 01/01/2011 - "Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: a randomized, open-label, parallel-group study." 01/01/2004 - "The aim of our study is to investigate retrospectively the gastrointestinal tolerance of sevelamer, their efficacy as phosphate binder and other parameters in a group of 89 patients with chronic renal failure in predialysis. "
4.	Kidney Diseases (Kidney Disease) 01/01/2013 - "Additional studies are needed to evaluate the potential effects of sevelamer treatment on nutritional status in chronic kidney disease (CKD) patients with elevated ET." 05/01/2012 - "From the results of this multicentric, comparative, randomized clinical study on sevelamer carbonate we can recommend that sevelamer carbonate may be used as a phosphate binder in Indian chronic kidney disease patients." 04/01/2009 - "The aim of study was the estimation of efficacy and safety of sevelamer treatment in children with chronic kidney disease with resistant hyperphsphatemia. " 07/01/2008 - "This study investigated the ability of sevelamer carbonate to control serum phosphorous in hyperphosphatemic patients who had chronic kidney disease and were not on dialysis. " 10/01/2004 - "We will review the published series, with special reference to the Sevelamer Treat to Goal trial and also discuss the new Kidney Disease Outcome Quality Initiative (K-DOQI) guidelines on the use of phosphate binders in chronic kidney disease."
5.	Renal Insufficiency (Renal Failure) 01/01/2010 - "Update and critical appraisal of sevelamer in the management of chronic renal failure." 01/01/2010 - "The aim of this study was to evaluate the ET-binding capacity of sevelamer carbonate in an animal model of renal failure. " 03/01/2012 - "Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective." 01/01/2010 - "In addition, preclinical models of renal failure and preliminary clinical data on hemodialysis patients suggest a potential benefit for bone with sevelamer. " 11/01/2010 - "Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III - V)."

Related Drugs and Biologics

1.	Calcium
2.	sevelamer (RenaGel)
3.	Calcium Carbonate (Limestone)
4.	calcium acetate (Phoslo)
5.	Phosphorus
6.	Vitamin D
7.	calcium phosphate
8.	lanthanum carbonate (Fosrenol)
9.	Adenine
10.	Salts

Related Therapies and Procedures

1.	Renal Dialysis (Hemodialysis)
2.	Peritoneal Dialysis
3.	Aftercare (After-Treatment)
4.	Drug-Eluting Stents
5.	Parathyroidectomy